EBMT 2024 | The therapeutic implications of shared pathophysiology in classical ITP and other thrombocytopenias
Simona Pagliuca, MD, PhD, Nancy University Hospital, Nancy, France, explores the shared pathophysiology between classical immune thrombocytopenia (ITP) and other forms of thrombocytopenia that occur after immunotherapy or cellular therapies. These disorders involve B- and T-cell dysfunction, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Dr Pagliuca suggests that treatments approved for ITP may also benefit those with more complex immune-mediated thrombocytopenic disorders. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
